Kristin Miller
Family · Nebraska City, NENPI 1942640073
Payments from drug & device makers
Across 182 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$774
- AstraZeneca$640
- Amgen$399
- Astellas Pharma US Inc$259
- Medtronic$240
- Lilly USA, LLC$214
- plus $974 from 25 others
What the payments were for
- Food & beverage$3,40097%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $774 |
| AstraZeneca | 8 | $640 |
| Amgen | 35 | $399 |
| Astellas Pharma US Inc | 10 | $259 |
| Medtronic | 1 | $240 |
| Lilly USA, LLC | 15 | $214 |
| Pfizer | 8 | $133 |
| Novo Nordisk | 7 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $90 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $72 |
| Bayer | 5 | $65 |
| Novartis | 3 | $45 |
| Sumitomo Pharma America, Inc. | 3 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Abbott | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Boehringer Ingelheim | 2 | $31 |
| Merck | 2 | $26 |
| GSK | 2 | $26 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $20 |
| Pulmonx Corporation | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Biogen | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,500 in reported general payments places this provider in the 90th percentile of 809 family providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 92 | $95,468 |
| JardianceEmpagliflozin | 79 | $79,905 |
| TrulicityDulaglutide | 49 | $72,804 |
| XareltoRivaroxaban | 60 | $46,628 |
| EliquisApixaban | 47 | $41,635 |
| MounjaroTirzepatide | 29 | $36,282 |
| FarxigaDapagliflozin Propanediol | 33 | $26,910 |
| JanuviaSitagliptin Phosphate | 13 | $23,773 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $19,610 |
| RybelsusSemaglutide | 12 | $15,393 |
| OxycontinOxycodone Hcl | 13 | $12,922 |
| MyrbetriqMirabegron | 24 | $11,325 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $10,900 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $10,446 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $107 | $110,861104 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $214 | $109,08678 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $31 | $90,805102 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $640 | $44,45977 claims |
| PfizerEliquis | $133 | $41,63547 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $26 | $33,88863 claims |
| MerckJanuvia | $26 | $23,77313 claims |
| Astellas Pharma US IncMyrbetriq | $259 | $11,32524 claims |
| AbbVieSavella | $774 | $5,72412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 809 family providers in Nebraska.
Other family in Nebraska City
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Michelle BrtekzwienerNorfolk$59K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Patricia TeeterWahoo$13K
- Mary MetzLincoln$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.